Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch
This article was originally published in The Tan Sheet
Executive Summary
One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight
You may also be interested in...
Von Eschenbach Confirmation Clears Holds At Tail-End Of Lame Duck
Andrew von Eschenbach's nomination to be FDA commissioner cleared the Senate by a comfortable 80-11 margin on Dec. 7, ending months of "holds" on the vote and opposition from both sides of the aisle
Congressional Oversight “Misunderstood” By Von Eschenbach – Grassley
Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a Sept. 22 final report